Bellevue Group AG Has $20.83 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bellevue Group AG lessened its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 50.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 171,317 shares of the biotechnology company's stock after selling 173,031 shares during the quarter. Bellevue Group AG owned approximately 0.18% of Sarepta Therapeutics worth $20,830,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SRPT. Manchester Capital Management LLC raised its stake in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at about $36,000. Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on SRPT. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Morgan Stanley dropped their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a report on Friday, April 11th. Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $157.95.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $63.51 on Friday. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25. The company's 50 day moving average price is $72.86 and its two-hundred day moving average price is $103.55. The stock has a market cap of $6.24 billion, a P/E ratio of 50.81 and a beta of 0.93. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.